Globeflex Capital’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-4,541
| Closed | -$972K | – | 497 |
|
|
2022
Q2 | $972K | Hold |
4,541
| – | – | 0.24% | 125 |
|
|
2022
Q1 | $1.29M | Sell |
4,541
-1,254
| -22% | -$387K | 0.26% | 108 |
|
|
2021
Q4 | $2.18M | Hold |
5,795
| – | – | 0.45% | 47 |
|
|
2021
Q3 | $2.39M | Sell |
5,795
-788
| -12% | -$327K | 0.52% | 36 |
|
|
2021
Q2 | $2.44M | Sell |
6,583
-198
| -3% | -$66.1K | 0.44% | 59 |
|
|
2021
Q1 | $1.97M | Buy |
6,781
+100
| +1% | +$27.8K | 0.36% | 76 |
|
|
2020
Q4 | $1.67M | Sell |
6,681
-443
| -6% | -$106K | 0.36% | 75 |
|
|
2020
Q3 | $1.61M | Sell |
7,124
-2,794
| -28% | -$580K | 0.43% | 56 |
|
|
2020
Q2 | $1.73M | Sell |
9,918
-5,049
| -34% | -$806K | 0.44% | 46 |
|
|
2020
Q1 | $1.89M | Sell |
14,967
-1,106
| -7% | -$166K | 0.58% | 26 |
|
|
2019
Q4 | $2.46M | Sell |
16,073
-3,545
| -18% | -$491K | 0.46% | 34 |
|
|
2019
Q3 | $2.6M | Buy |
19,618
+2,207
| +13% | +$296K | 0.57% | 28 |
|
|
2019
Q2 | $2.47M | Buy |
17,411
+945
| +6% | +$128K | 0.51% | 34 |
|
|
2019
Q1 | $2.39M | Sell |
16,466
-1,969
| -11% | -$259K | 0.51% | 34 |
|
|
2018
Q4 | $2.09M | Sell |
18,435
-434
| -2% | -$54.3K | 0.5% | 39 |
|
|
2018
Q3 | $2.54M | Sell |
18,869
-143
| -0.8% | -$17.6K | 0.5% | 34 |
|
|
2018
Q2 | $2.13M | Sell |
19,012
-1,423
| -7% | -$154K | 0.44% | 48 |
|
|
2018
Q1 | $2.18M | Sell |
20,435
-6,160
| -23% | -$664K | 0.46% | 44 |
|
|
2017
Q4 | $2.91M | Sell |
26,595
-1,205
| -4% | -$131K | 0.81% | 7 |
|
|
2017
Q3 | $3M | Sell |
27,800
-16,044
| -37% | -$1.65M | 0.86% | 8 |
|
|
2017
Q2 | $4.43M | Buy |
43,844
+4,558
| +12% | +$420K | 1.09% | 5 |
|
|
2017
Q1 | $3.53M | Sell |
39,286
-1,324
| -3% | -$112K | 0.84% | 7 |
|
|
2016
Q4 | $3.09M | Sell |
40,610
-627
| -2% | -$47.6K | 0.77% | 9 |
|
|
2016
Q3 | $3.44M | Sell |
41,237
-330
| -0.8% | -$27.7K | 0.86% | 8 |
|
|
2016
Q2 | $3.43M | Buy |
41,567
+260
| +0.6% | +$21.4K | 0.94% | 5 |
|
|
2016
Q1 | $3.14M | Sell |
41,307
-272
| -0.7% | -$20.1K | 0.84% | 9 |
|
|
2015
Q4 | $3.34M | Sell |
41,579
-10,528
| -20% | -$759K | 0.89% | 8 |
|
|
2015
Q3 | $3.31M | Sell |
52,107
-2,467
| -5% | -$177K | 0.71% | 20 |
|
|
2015
Q2 | $3.84M | Sell |
54,574
-3,456
| -6% | -$256K | 0.7% | 16 |
|
|
2015
Q1 | $4.6M | Sell |
58,030
-2,358
| -4% | -$174K | 0.88% | 8 |
|
|
2014
Q4 | $3.84M | Sell |
60,388
-72,423
| -55% | -$4.54M | 0.74% | 12 |
|
|
2014
Q3 | $7.93M | Buy |
132,811
+111,070
| +511% | +$6.35M | 0.9% | 12 |
|
|
2014
Q2 | $1.16M | Hold |
21,741
| – | – | 0.13% | 198 |
|
|
2014
Q1 | $1.31M | Sell |
21,741
-29
| -0.1% | -$1.69K | 0.15% | 163 |
|
|
2013
Q4 | $1.15M | Sell |
21,770
-1,288
| -6% | -$64.7K | 0.14% | 182 |
|
|
2013
Q3 | $1.07M | Hold |
23,058
| – | – | 0.14% | 198 |
|
|
2013
Q2 | $946K | Buy |
+23,058
| New | +$988K | 0.13% | 207 |
|
Other funds holding CRL
JSP
Globeflex Capital's CRL Position: Q3 2022 in Review
Globeflex Capital sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 4,541 shares — an estimated $972K sold.
Globeflex Capital first reported a position in CRL in Q2 2013 and held it in 37 quarters. The position peaked at $7.93M in Q3 2014. 584 funds tracked by Wall St. Rank hold CRL as of Q3 2022.
- Globeflex Capital reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
- Globeflex Capital sold 4,541 Charles River Laboratories shares in Q3 2022, an estimated $972K.
- Globeflex Capital first reported a position in Charles River Laboratories in Q2 2013 and held it in 37 quarters.
- Globeflex Capital's Charles River Laboratories position peaked at $7.93M in Q3 2014.
- 584 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.
Based on Globeflex Capital's 13F filing for Q3 2022, filed 14 Nov 2022.